LGALS9 and neoplasm: In the basal subtype, both tumor cells and macrophages showed enhanced LGALS9-HAVCR2, SPP1-CD44 interactions with CD8+ T cells (Figure 5B), which are known to suppress T-cell functions 24, 25.